The goal of this Translational Program Project Grant is to advance the biologic understanding and therapeutic application of inhaled carbon monoxide (CO) in sepsis-induced ALI. Core B (the Clinical Studies Coordination Core) will provide important resources and support for the Project Investigators in carrying out the proposed Translational Studies. Specifically, this core will provide human samples from well-phenotyped subjects to investigators in Projects 1-4 and serve as the Data Coordinating Center (DCC) for the Phase I safety and proof-of-concept trials in administering inhaled CO to patients with sepsis-induced ALI. Objective 1: To identify patients with the systemic inflammatory response syndrome (SIRS), sepsis, and sepsis-induced acute lung injury (ALI);to collect and store plasma, RNA, and primary cells from subjects in a clinical biorepository;and to provide biostatistical support for Projects 1-4 for the analysis and interpretation of studies performed using these specimens. This Core will provide investigators in Projects 1-4 with uniformly processed clinical samples from well-characterized critically ill patients from the BWH Medical ICU. We anticipate that we will enroll at least 1,000 subjects (over 5 years). Objective 2: To serve as the DCC for the Phase 1 first-in-ALI safety study for inhaled CO in sepsis induced ALI in Project 1 and proof-of-concept study with collection of muscle biopsies after inhaled CO in Project 2. Collection of samples as in Objective 1 will be undertaken pre- and post-CO exposure for distribution to the investigators in Projects 1-4. As the DCC for the clinical trials in Years 3-5, we will provide support to the investigators at BWH, MGH, and DUMC in carrying out these trials. In years 1-2, we will submit the IND and IRB applications and develop the infrastructure for initiating the trials. Once the trial is initiated, we will manage the database, process adverse events, and produce regular reports to the DSMB, FDA, and investigators. We will also collect and analyze data from Project investigators regarding levels of biomarkers in clinical samples. Overall Objective: By centralizing clinical trials oversight, clinical sample collection, and phenotyping by experienced and expert investigators, well-characterized and uniformly processed clinical samples can be provided to investigators from Projects 1-4 to facilitate their translational research aims. Importantly, data from the Phase I safety and proof-of-concept studies will form the basis for a Phase ll/lll clinical trial in the 2nd 5-year cycle of this translational Program Project Grant.

Public Health Relevance

Sepsis-induced ALI is a condition with high morbidity and mortality and with limited available treatment options. This Translational Program Project Grant proposes to advance the understanding and application of a novel therapeutic modality, inhaled carbon monoxide, in these critically ill patients. This Core will play a key role in facilitating the translational aspects of this proposal for all of the proposed projects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL108801-02
Application #
8380533
Study Section
Special Emphasis Panel (ZHL1-PPG-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$332,960
Indirect Cost
$136,479
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Ghanta, Sailaja; Kwon, Min-Young; Rosas, Ivan O et al. (2018) Mesenchymal Stromal Cell Therapy: Does the Source Matter? Crit Care Med 46:343-345
Baron, Rebecca M; Kwon, Min-Young; Castano, Ana P et al. (2018) Frontline Science: Targeted expression of a dominant-negative high mobility group A1 transgene improves outcome in sepsis. J Leukoc Biol 104:677-689
Shu, Chang; Huang, He; Xu, Ying et al. (2018) Pressure Overload in Mice With Haploinsufficiency of Striated Preferentially Expressed Gene Leads to Decompensated Heart Failure. Front Physiol 9:863
Harrington, John S; Schenck, Edward J; Oromendia, Clara et al. (2018) Acute respiratory distress syndrome without identifiable risk factors: A secondary analysis of the ARDS network trials. J Crit Care 47:49-54
Siempos, Ilias I; Ma, Kevin C; Imamura, Mitsuru et al. (2018) RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury. JCI Insight 3:
Rosas, Ivan O; Goldberg, Hilary J; Collard, Harold R et al. (2018) A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest 153:94-104
Ma, Kevin C; Schenck, Edward J; Pabon, Maria A et al. (2018) The Role of Danger Signals in the Pathogenesis and Perpetuation of Critical Illness. Am J Respir Crit Care Med 197:300-309
Schenck, Edward J; Oromendia, Clara; Torres, Lisa K et al. (2018) Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials. Chest :
Schenck, Edward J; Ma, Kevin C; Murthy, Santosh B et al. (2018) Danger Signals in the ICU. Crit Care Med 46:791-798
Chen, Xi; Wang, Shaojun; Xu, Haiwei et al. (2017) Evidence for a retinal progenitor cell in the postnatal and adult mouse. Stem Cell Res 23:20-32

Showing the most recent 10 out of 85 publications